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The binding of androgens and structurally related analogues to the androgen receptor was 
studied. The in vitro experiments were carried out with cytosol of castrated rat prostate, using 
[3H]RI881 (methyltrienolone) as radioligand. The binding parameters measured were Kd=l.25 
xl0 -"~ u and Bm,,x=l 11 fmol (mg protein) -~. Ligand specificity was confirmed by competition 
experiments with known androgen, oestrogen and progestogen ligands. The receptor binding 
of substituted steroids was studied. The RBAs (relative binding affinities) of our recently 
synthetized 16-alkyl steroids were low. The only exception was the 17fl-hydroxy-16fl- 
methylestr-4-en-3-one, which exhibited the remarkable RBA of 22.9%. 
© 1995 The Italian Pharmacological Society 
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INTRODUCTION 
Diversities in the mechanisms of action of steroid hor- 
mones have emerged in recent years [1]. The new 
mechanisms proposed do not ignore the classical 
action of steroids: they may occur either in conjunc- 
tion with this, or as an alternative mechanism. 
The major mechanism in the classical concept 
involves steroid hormone binding to the intracellular 
receptor, activation of the receptor, and binding of the 
steroid-receptor complex to DNA, followed by gene 
activation [2]. 
Besides the direct methods of receptor characteriz- 
ation, indirect means of obtaining information are 
likewise very important and useful in drug research. 
Different overlapping aims can be distinguished in the 
study of ligand-receptor complexes [3]. The design of 
compounds for use as potential drugs is possibly the 
most spectacular one. The identification of ligands to 
be used as probes to detect he steroid receptor is very 
important from a therapeutical point of view. Com- 
parisons between ligands with similar affinities but 
different activities and/or specificities, can help 
towards a better understanding of the molecular mech- 
anism. Study of the structural requirements for ligand 
binding, and thereby mapping of the hormone-binding 
site of the receptor, is possible by comparing the 
structures and relative binding affinities of modified 
steroids. 
Correspondence to: Dr E. Mesk6, Department of Organic 
Chemistry, J6zsef Attila University, D6m t6r 8, H-6720 Szeged, 
Hungary. 
We recently reported the preparation of 16-alkyl 
steroids and their in vitro inhibitory effects on 5tx- 
reductase. We now describe the in vitro binding of 
these compounds to the androgen receptor. 
MATERIALS AND METHODS 
Steroids 
Methyltrienolone (R1881, 17fl-hydroxy-17a- 
methylestra-4,9,11-trien-3-one) (compound 1) and 
[3H]R1881 (S.A.=86 Ci mmol -I) were obtained from 
New England Nuclear Research Products (Boston, 
USA). Unlabelled ligands were purchased from Sigma 
Chemical Company (St. Louis, USA). The studied 
compounds that we earlier synthesized are listed in 
Table I. Their chemical structures are given in Fig. 1. 
All steroids have been found homogeneous by chrom- 
atographic methods. Their preparation and purifi- 
cation just as data on the purity (C, H analysis; ~H and 
t3C NMR) have been published earlier [4-8]. 
TEDGM+PMSF buffer 
Composition: 50 mM Tris-HCl (2-amino-2- 
hydroxymethyl-l,3-propanediol hydrochloride), 1 mM 
EDTA (ethylenediaminetetraacetic acid), 1 mM DTT 
(dithiothreitol), 10% glycerol, 10 mM Na2MoO4, 1 mM 
PMSF (phenylmethylsulfonyl fluoride) and 0.02% 
NaN3 (pH: 7.4). 
Dextran coated charcoal (DCC) 
Three hundred and thirty three milligrams of Norit- 
A (activated carbon) and 33 mg dextran T-70 in 
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100 ml TEDGM+PMSF buffer; always freshly 
prepared. 
Saturat ion exper iments  
Prostates of Wistar rats (240-320 g) were removed 
surgically 24 h after castration. Homogenization was 
performed in TEDGM+PMSF buffer (mass four times 
the mass of prostate tissue) with an UItra-Turrax 
(Janke and Kunkel, Germany). The homogenate was 
centrifuged at 4°C, with 18 000g for 30 min. 
The protein content of the post-mitochondrial 
supernatant (PMS) was determined according to 
Lowry et al. [9]. 
Varying concentrations (from 0.1 nM up to 2.0 nM) 
of the ligand [3H]RI881 were added to 0. I ml PMS 
sample, which was then diluted to 0.4 ml. After mix- 
ing, it was incubated for 18 h at 4°C. The unbound 
radioactivity was removed by centrifugation after the 
addition of 0.6 ml charcoal suspension. The radioac- 
tivity of the supernatant gave the total ligand binding 
(T). The non-specific binding (NSB) was measured in 
a parallel assay tube in the presence of excess unlab- 
elled ligand (400 nM R1881). The specific binding of 
the ligand is the difference between the total binding 
and the nonspecific binding. These values are 
expressed in terms of femtomoles per milligram of 
protein. 
Scatchard transformation of the specific binding 
data resulted in a linear plot. B,,,~ (the amount of bind- 
ing observed at the saturating concentration of 
radioligand) and Kd (the binding equilibrium constant, 
i.e. the concentration at which half the receptor sites 
are occupied) were obtained by linear regression 
analysis. 
Compet i t ion exper iments  
In competition experiments (Fig. 2), 2 nM 
[3H]R1881 was incubated in the presence of various 
concentrations of the inhibitor. The abilities of com- 
pounds to inhibit the specific binding of the radioli- 
gand are characterized quantitatively by their 1C5, 
values (tile concentration of inhibitor at which 50% of 
the specific radioligand binding is inhibited). IC5,, 
values were determined by linear regression analysis 
from logit-log plots. Relative binding affinities are 
defined by 
RBA = [ICs.([3HIR 1881 )/IC~.(inhibitor)l x 100 
RESULTS AND DISCUSSION 
The binding energy regarding the steroid hormone 
receptors is around -12 to -15 kcal tool -~, correspond- 
ing to a dissociation constant of 10-"-10 -~ M. The H- 
bonds at the C-3 and C-17 ends of the molecule sup- 
ply one-third to one-half of this energy, while the van 
der Waals interactions provide the remainder. 
For example, the mean intermolecular van der 
Waals energy is around -3 kcal mol -~ for a suitably 
located methyl group. On that account many methyl- 
substituted steroids with the functional groups in diff- 
erent positions (e.g. at C-2, C-6, C-7 or C-17) were 
synthesized and studied [10]. Among the drugs inter- 
acting with the androgen receptor are several which 
contain a methyl or ethyl function, e.g. oxendolone 
(Takeda, ethyl at C-16), megestrol acetate (Syntex, 
methyl at C-6) and rosterolone (Schering, methyl at 
C-l, propyl at C-17). 
Besides the nature of the substituent, he 3D struc- 
ture of the whole molecule may be crucial as regards 
the biological activity. The conformation of the ster- 
ane skeleton can play an important role, and thus 
small changes in steroid conformation can modify the 
affinity and specificity [11]. Further, the stereoiso- 
mers of a given compound usually differ greatly in 
their biological properties (both dynamic and kinetic 
properties) [12]. Chiral drugs and their ethical and 
Table I 
List of compounds tudied 
Structure no. Compound Synthesis 
(in Fig. 1) 
4 17fl-hydroxy- 16fl-methylandrost-4-en-3-one ref. 4 
5 17fl-hydroxy- 16tx-methylandrost-4-en-3-one ref. 4 
6 17fl-hydroxy- 16,16-dimethylandrost-4-en-3-one ref. 5 
7 16fl, 17fl-epoxymethyleneandrost-4-en-3-one ref. 8 
9 17a-hydroxy- 16fl-methylandrost-4-en-3-one ref. 4 
10 17 a-hydroxy- 16a-methylandrost-4-en-3-one ref. 4 
12 17fl-hydroxy- 16fl-methylestr-4-en-3-one ref. 7 
13 17fl-hydroxy- 16,16-dimethylestr-4-en-3-one ref. 6 
14 16,16-dimethyl-3-oxoestr-4-en-17fl-yl acetate ref. 6 
15 17a-hydroxyestr-4-en-3-one (nor-epitestosterone) ref. 8 
16 17 a-hydroxy- 16fl-methylestr-4-en-3-one ref. 7 
17 17o¢-hydroxy- 16a-methylestr-4-en-3-one ref. 7 
20 17fl-hydroxy- 16,16-dimethyi-5 a-androstan-3 -one ref. 5 
22 16fl-ethyl-5 tz-androstane-3fl, 17fl-diol 
23 16,16-dimethyl-5 a-androstane-3fl, 17fl-diol ref.5 
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Fig. 1. Chemical structures ofcompounds studied. 
regulatory aspects have been at the focus of develop- 
ment and marketing for many years [13]. 
Both of the above aspects are involved in our stud- 
ies of the receptor binding of different, pure isomers 
of 16-alkylated steroids to the androgen receptor. 
Tritiated natural steroid hormones are usually 
applied as ligands in binding experiments. In the case 
of the androgen receptor, the synthetic ligand 
[3H]R1881 is widely used as its affinity is higher than 
that of tritiated dihydrotestosterone. It does not bind 
to sex-hormone-binding globulin and it is not meta- 
bolized during incubation [14-16]. As R1881 is not a 
ligand specific for the androgen receptor, but binds 
Tissue sample: prostate from rats after castration 
Homogenization: Ultra-Turrax, 8 x 1 min 
Centrifugation: 18000 g, 30 min, 4°C 
Supernatant = PMS ~ Protein determination (Lowry et  a l . )  
. . . . . .  ; protein - 25 mg prostate) 
2 nM [3H]R1881 
400 nM 'cold' R1881 
Incubation: 18 h, 4°C 
+0.6 ml DCC suspension 
T NSB 
Centifugation: 5000 g, 15 min, 4°C 
0.5 ml supernatant forradioactivity measurement 
Androgen receptor content: T-NSB 
[fmol (rag protein) -1] 
Fig. 2. Assay for androgen receptor binding in cytosol of 
rat prostate. 
with comparably high affinity to the progesterone 
receptor too, it is possible to study both receptors sim- 
ultaneously [17] in human tissues. The rat prostate 
does not contain the progesterone r ceptor. This per- 
mits the use of a simple assay method. 
The prostate gland is one of the major androgen- 
dependent organs. The androgen receptor content of 
the castrated rat prostate is higher than that of human 
BPH (benign prostate hyperplasia) prostate cytosol. 
The average receptor content for different animal 
groups was found to be 94.8+3.9 fmol (mg protein) -z, 
while that for the human BPH prostate varied in the 
interval 21-38 fmol (mg protein) -~. The rat prostate is 
therefore commonly applied in androgen receptor 
binding experiments. 
Receptor-ligand interactions have been charac- 
terized by the values of Bmax and Kd. The binding of 
the ligand [3H]R1881 to the androgen receptor is satu- 
rable (Fig. 3), indicating a finite number of binding 
sites, Bmax=l 11 fmol (mg protein) -~. The binding affin- 
ity meets the criterion of the nanomolar ange for 
receptor identification, with Kd=l.25x10 -'° M. 
The results of competition experiments charac- 
terize the pharmacology of the receptor. The data in 
Table II confirm the ligand specificity. Neither oes- 
trogen nor progestogen-type ligand display binding. 
Most of the compounds investigated (structurally 
related analogues of the natural androgens) exhibit 
little or no receptor binding. The only noteworthy 
exception is 17fl-hydroxy-16fl-methylestr-4-en-3-one 
(compound 12). Exact values of ICso and RBA are 
given in Table III. 
The basic importance of the 17fl-hydroxy-3-one 
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increase, from 42.80 (compound 3) to 92.20 
(compound 11). A similar effect can be observed for 
16fl-methyltestosterone (compound 4). Elimination of 
the C-10 methyl group enhances the RBA from 3.90 
(compound 4) to 22.90 (compound 12). It is known 
from X-ray crystallographic data [18] and molecular 
geometry calculations [I 9, 20] that ring A of 19-norte- 
stosterone undergoes a 'flip-flap' interconversion to a 
half-chair conformation. This interconversion to the 
very different half-chair conformation explains the 
Fig. 3. (A) Saturation curve and (B) Scatchard plot of 
[3H]R1881 binding in rat prostatic PMS. 
Table III 
Relative binding affinities of substituted steroids at 
4°C for cytosol androgen receptor of rat prostate in 
presence of [3H]RI881 as radioligand 
Compounds Range of IC5o (nM)+SD RBA (%) 
tested concentration 
(nM) 
R1881 1-20 2.86±0.35 100.00 
3 2-20 6.68+-0.06 42.80 
4 10-120 73.5+-18.3 3.90 
5 200-2000 >1000 <0.30 
6 200-2000 >1000 <0.30 
7 200-2000 >1000 <0.30 
Bound [3H]R1881 (r~) 8 
9 
10 
structure is confirmed by compound 7. The 16fl, 17fl- 
epoxymethylene function results in a loss of binding 
affinity. The introduction of a 16fl-methyl substituent 15 
into testosterone (compound 3 ---> compound 4) 16 
decreases the binding from 42.80 to 3.90. The 16a- 17 
methyl isomer (compound 5) and the gem-dimethyl 18 
analog (compound 6) are practically not bound to the 19 
androgen receptor. The 16fl-methyl group decreases 20 
the binding of 19-nortestosterone too, but to a much 
lower extent, from 92.20 (compound 11) to 22.90 21 
(compound 12). The consequence of removing the 22 
23 
C-10 methyl group from testosterone is a binding 
200-2000 824±42.9 0.35 
200-2000 >1000 <0.30 
200-2000 >1000 <0,30 
11 2-20 3.10+-0.80 92.20 
12 5-50 12.5±1.6 22.90 
13 50-2000 >1000 <0.30 
14 500-2000 >1000 <0.30 
200-1000 203.8+-49.8 1.40 
500-2000 848.3+-40.2 0.34 
250-2000 223.8+-17.3 1.30 
2-20 3.0+-0.46 95.30 
5-160 49.8+-13.2 5.70 
50-1000 523.3+-40.8 0.50 
50-800 73.5+-8.5 3.90 
50-2000 >1000 <0.30 
50-2000 >1000 <0.30 
Table II 
Relative binding affinities at 4°C for cytosoi androgen receptor of rat prostate in presence of [3H]R1881 as 
radioligand 
Ligands Range of IC5o (nM)+-SD RBA (%) 
concentration ( t~) 
Methyltrienolone (compound 1) 1-20 2.68+_0.35 100.00 
Cyproterone acetate (compound 2) 2-200 148.0+ 19.1 1.93 
Testosterone (compound 3) 2-20 6.68+-0.06 42.80 
Dihydrotestosterone (compound 19) 2-20 3.00+0.46 95.30 
Estradiol-17fl 50-1000 294.0+20.3 0.97 
Testosterone propionate 50-1000 338+53.3 0.85 
Progesterone 50-1000 663+203 0.43 
Estrone 50-2000 > 1000.0 <0.30 
Estriol 50-2000 > 1000.0 <0.30 
Ketoconazole 50-2000 >1000.0 <0.30 
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enhanced binding of 16fl-methyl-19-nortestosterone 
(compound 12) as well. The RBA of epi-testosterone 
(compound 8) is likewise lower than that of nor-epite- 
stosterone (compound 15). However, the ~ position of 
the 17-hydroxy group diminishes the binding affinity 
so much that even the increased value is very low 
(1.40 for compound 15). All other analogues with a 
17a-hydroxy group (compounds 9, 10, 16 and 17) 
undergo practically no binding. While dihydrotestos- 
terone (compound 18) has an improved affinity of 
95.30 as compared with 42.80 for testosterone, further 
modification (the lack of the angular methyl group 
or 16-methylation) lead to compounds 19 and 20 
with dramatically decreased binding. 16-alkylation 
(compound 22: fl-ethyl, or compound 23: dimethyl) of 
5o~-androstane-3fl, 17fl-diol (compound 21) results in 
a loss of binding ability. 
Receptor binding is essential as regards biological 
activity. Thus, the IC5o and RBA values are important 
data, but they do not reveal the pharmacological type 
(agonist or antagonist) of the ligands. Additionally the 
validation of receptor binding requires in vivo biologi- 
cal tests to study the correlation of binding with bio- 
logical dose-response curves. 
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